Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
August 29 2016 - 8:30AM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will present a business overview and an update on Enanta’s
research and development pipeline at each of the following investor
conferences:
- September 8, 11:25 a.m. ET – Baird
2016 Global Healthcare Conference, New York City
- September 12, 9:20 a.m. ET – Morgan
Stanley Global Healthcare Conference, New York City
A live webcast and replay of each presentation will be
accessible by visiting the “Calendar of Events” section on the
“Investors” page of Enanta’s website at www.enanta.com. The webcast
replay will be available following each presentation and will be
archived for approximately 30 days.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta’s research and development is currently focused on four
disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV),
Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial
Virus (RSV).
Enanta has developed direct-acting-antiviral (DAA) inhibitors
designed for use against HCV. Enanta’s protease inhibitors,
developed through its collaboration with AbbVie, include
paritaprevir, which is contained in AbbVie’s marketed DAA regimens
for HCV, and ABT-493, Enanta’s second protease inhibitor, which
AbbVie is developing in phase 3 studies in combination with
ABT-530, AbbVie’s NS5A inhibitor. Enanta has also discovered a
cyclophilin inhibitor, EDP-494, a novel, host-targeting mechanism
for HCV, which is now in phase 1 clinical development, and EDP-305,
an FXR agonist, which Enanta plans to advance into clinical
development for NASH later in 2016. In addition, Enanta has early
lead candidates for HBV and RSV in preclinical testing. Please
visit www.enanta.com for more information on Enanta’s programs and
pipeline.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160829005049/en/
Enanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024